Health
FDA panel advises against black-box warning for ADHD drugs
NEWS IN BRIEF — Posted April 17, 2006
A Food and Drug Administration advisory panel decided March 22 against recommending that a black-box warning be placed on labels for several stimulant drugs often prescribed for children and adults with attention-deficit/hyperactivity disorder. Although certain adverse events were identified by the committee, most notably hallucinations and psychotic episodes, the risk level did not rise to the need for a black-box warning, said Robert Nelson, MD, PhD, chair of the Pediatric Advisory Committee and attending intensivist at Children's Hospital of Philadelphia.
The FDA's Drug Safety and Risk Management Advisory Committee had recommended in February that a black-box warning for cardiovascular risk be placed on such drugs as Adderall, Ritalin and Concerta. While a warning of possible heart risks posed by the medications was considered, the pediatric committee ultimately decided stimulants pose a lower risk for most younger patients than for adults.
Because the FDA is changing the way medication labels are organized to highlight important safety considerations, necessary precautions could likely be taken care of in the re-ordered labels, said Dr. Nelson.
A guide to help parents understand the risks posed by the drugs likely will be forthcoming, said Robert Temple, MD, director of FDA's drug evaluation center's Office of Medical Policy. The FDA will determine whether a black-box warning is appropriate.
Note: This item originally appeared at http://www.ama-assn.org/amednews/2006/04/17/hlbf0417.htm.












